<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00711230</url>
  </required_header>
  <id_info>
    <org_study_id>DermaVir Phase II</org_study_id>
    <secondary_id>2007-001955-20</secondary_id>
    <nct_id>NCT00711230</nct_id>
  </id_info>
  <brief_title>Repeated DermaVir Immunizations in HIV-1 Infected Treatment-naïve Patients</brief_title>
  <acronym>GIEU006</acronym>
  <official_title>A Phase II Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antiretroviral Activity of DermaVir Patch (LC002) in Treatment-Naïve HIV-1-Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genetic Immunity</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Genetic Immunity</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      DermaVir is a synthetic pathogen-like nanomedicine. The active pharmaceutical ingredient is a
      single plasmid DNA expressing fifteen HIV antigens that assemble to HIV-like particles. These
      particles are safe; replication, integration and reverse transcription deficient. DermaVir is
      targeted to Langerhans cells by topical administration with DermaPrep. Langerhans cells with
      DermaVir migrate to lymph nodes and induce HIV-specific T cells that can kill HIV-infected
      cells.

      GIEU006 is a Phase II randomized, placebo-controlled, dose-finding, double-blinded,
      multicenter study to assess the safety, tolerability, immunogenicity, and preliminary
      antiretroviral activity of DermaVir in antiretroviral therapy naïve adults with
      HIV-infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients were randomized into one of the following 6 arms:

        -  Arm 1: Low dose DermaVir (0.2 mg DNA in 2 DermaPrep patches, n=9)

        -  Arm 2: Low dose Placebo (2 DermaPrep patches, n=3)

        -  Arm 3: Medium dose DermaVir (0.4 mg DNA in 4 DermaPrep patches, n=9)

        -  Arm 4: Medium dose Placebo (4 DermaPrep patches, n=3)

        -  Arm 5: High dose DermaVir (0.8 mg DNA in 8 DermaPrep patches, n=9)

        -  Arm 6: High dose Placebo (8 DermaPrep patches, n=3) DermaPrep Patch size: 80 cm2.
           DermaVir Standard Unit per patch is 0.1 mg DNA = 0.8 mL of DermaVir nanomedicine.

      The patch sites for immunization are preferably the left or right upper back and left or
      right upper ventral thigh. The same skin sites should be used for all immunizations.

      Immunization schedule (Days): 0, 42, 84, and 126.

      The total DermaVir dose:

        -  Low dose: 0.8 mg DNA

        -  Medium dose: 1.6 mg DNA

        -  High Dose: 3.2 mg DNA

      DermaVir immunizations were administered over an 18-week period Primary endpoint: 24 weeks
      Safety follow up: 234 weeks
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2008</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of participants with primary safety endpoint</measure>
    <time_frame>24 weeks</time_frame>
    <description>Primary safety endpoint: occurrence of at least two &gt; Grade 3 adverse event including signs/symptoms, lab toxicities, and/or clinical events that is possibly or definitely related to study treatment (as judged by the GIEU006 team, including site clinicians on the team, blinded to treatment arm) any time from the first day of study treatment until 42 days after the last study vaccine administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HIV-1 RNA</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+ and CD8+ T-cell counts</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-specific memory T cell responses</measure>
    <time_frame>24 weeks</time_frame>
    <description>Measured with Precursors with High Proliferative Capacity (PHPC) assay (Calarota et al. HIV-1-Specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals. J Immunol 2008;180:5907-15)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>1: Low dose DermaVir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage: 0.2 mg DNA
Dosage form: 1.6 mL DNA/PEIm nanomedicine
Administration with 2 DermaPrep patches
Frequency: every six weeks
Duration: 18 weeks (4 DermaVir treatments)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2: Low dose Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage form: 1.6 mL Placebo
Administration with 2 DermaPrep patches
Frequency: every six weeks
Duration: 18 weeks (4 Placebo treatments)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3: Medium dose DermaVir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage: 0.4 mg DNA
Dosage form: 3.2 mL DNA/PEIm nanomedicine
Administration with 4 DermaPrep patches
Frequency: every six weeks
Duration: 18 weeks (4 DermaVir treatments)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4: Medium dose Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage form: 1.6 mL Placebo
Administration with 4 DermaPrep patches
Frequency: every six weeks
Duration: 18 weeks (4 Placebo treatments)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5: High dose DermaVir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage: 0.8 mg DNA
Dosage form: 6.4 mL DNA/PEIm nanomedicine
Administration with 8 DermaPrep patches
Frequency: every six weeks
Duration: 18 weeks (4 DermaVir treatments)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6: High dose Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage form: 6.4 mL Placebo
Administration with 8 DermaPrep patches
Frequency: every six weeks
Duration: 18 weeks (4 Placebo treatments)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DermaVir</intervention_name>
    <arm_group_label>1: Low dose DermaVir</arm_group_label>
    <arm_group_label>3: Medium dose DermaVir</arm_group_label>
    <arm_group_label>5: High dose DermaVir</arm_group_label>
    <other_name>LC002</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>glucose/dextrose</description>
    <arm_group_label>2: Low dose Placebo</arm_group_label>
    <arm_group_label>4: Medium dose Placebo</arm_group_label>
    <arm_group_label>6: High dose Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main inclusion Criteria:

          -  HIV antibody positive

          -  Plasma HIV RNA value ≥5,000 copies/mL and ≤ 150,000 c/mL

          -  Antiretroviral therapy naïve

          -  Documented CD4+ T-cell count at screening ≥400 cells/mm3

        Main exclusion Criteria:

          -  No skin disease

          -  No tattoos, or changes in pigmentation at the selected skin immunization sites

          -  No acute or chronic illness (e.g Hepatitis C)

          -  No chronic autoimmune diseases

          -  No treatment with any immune modulating agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Van Lunzen, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ifi-Medizin GmbH at the Asklepios Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICH Grindel</name>
      <address>
        <city>Hamburg</city>
        <zip>20146</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.geneticimmunity.com</url>
    <description>Genetic Immunity's homepage</description>
  </link>
  <link>
    <url>http://hivandhepatitis.com/2010_conference/AIDS2010/docs/post/lunzen.pdf</url>
    <description>DermaVir for initial treatment of HIV-infected subjects demonstrates preliminary safety, immunogenicity and HIV-RNA reduction versus placebo immunization</description>
  </link>
  <reference>
    <citation>Lisziewicz J, Bakare N, Calarota SA, Bánhegyi D, Szlávik J, Ujhelyi E, Tőke ER, Molnár L, Lisziewicz Z, Autran B, Lori F. Single DermaVir immunization: dose-dependent expansion of precursor/memory T cells against all HIV antigens in HIV-1 infected individuals. PLoS One. 2012;7(5):e35416. doi: 10.1371/journal.pone.0035416. Epub 2012 May 9.</citation>
    <PMID>22590502</PMID>
  </reference>
  <reference>
    <citation>Lisziewicz J, Tőke ER. Nanomedicine applications towards the cure of HIV. Nanomedicine. 2013 Jan;9(1):28-38. doi: 10.1016/j.nano.2012.05.012. Epub 2012 May 30. Review.</citation>
    <PMID>22659241</PMID>
  </reference>
  <reference>
    <citation>Lőrincz O, Tőke ER, Somogyi E, Horkay F, Chandran PL, Douglas JF, Szebeni J, Lisziewicz J. Structure and biological activity of pathogen-like synthetic nanomedicines. Nanomedicine. 2012 May;8(4):497-506. doi: 10.1016/j.nano.2011.07.013. Epub 2011 Aug 10.</citation>
    <PMID>21839051</PMID>
  </reference>
  <reference>
    <citation>Toke ER, Lorincz O, Somogyi E, Lisziewicz J. Rational development of a stable liquid formulation for nanomedicine products. Int J Pharm. 2010 Jun 15;392(1-2):261-7. doi: 10.1016/j.ijpharm.2010.03.048. Epub 2010 Mar 25.</citation>
    <PMID>20347027</PMID>
  </reference>
  <reference>
    <citation>Lori F. DermaVir: a plasmid DNA-based nanomedicine therapeutic vaccine for the treatment of HIV/AIDS. Expert Rev Vaccines. 2011 Oct;10(10):1371-84. doi: 10.1586/erv.11.118.</citation>
    <PMID>21988301</PMID>
  </reference>
  <reference>
    <citation>Somogyi E, Xu J, Gudics A, Tóth J, Kovács AL, Lori F, Lisziewicz J. A plasmid DNA immunogen expressing fifteen protein antigens and complex virus-like particles (VLP+) mimicking naturally occurring HIV. Vaccine. 2011 Jan 17;29(4):744-53. doi: 10.1016/j.vaccine.2010.11.019. Epub 2010 Nov 23.</citation>
    <PMID>21109034</PMID>
  </reference>
  <reference>
    <citation>Calarota SA, Weiner DB, Lori F, Lisziewicz J. Induction of HIV-specific memory T-cell responses by topical DermaVir vaccine. Vaccine. 2007 Apr 20;25(16):3070-4. Epub 2007 Jan 22.</citation>
    <PMID>17292518</PMID>
  </reference>
  <reference>
    <citation>Lisziewicz J, Trocio J, Whitman L, Varga G, Xu J, Bakare N, Erbacher P, Fox C, Woodward R, Markham P, Arya S, Behr JP, Lori F. DermaVir: a novel topical vaccine for HIV/AIDS. J Invest Dermatol. 2005 Jan;124(1):160-9.</citation>
    <PMID>15654970</PMID>
  </reference>
  <reference>
    <citation>Lori F, Trocio J, Bakare N, Kelly LM, Lisziewicz J. DermaVir, a novel HIV immunisation technology. Vaccine. 2005 Mar 18;23(17-18):2030-4.</citation>
    <PMID>15755566</PMID>
  </reference>
  <reference>
    <citation>Lisziewicz J, Trocio J, Xu J, Whitman L, Ryder A, Bakare N, Lewis MG, Wagner W, Pistorio A, Arya S, Lori F. Control of viral rebound through therapeutic immunization with DermaVir. AIDS. 2005 Jan 3;19(1):35-43.</citation>
    <PMID>15627031</PMID>
  </reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 4, 2008</study_first_submitted>
  <study_first_submitted_qc>July 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2008</study_first_posted>
  <last_update_submitted>February 19, 2013</last_update_submitted>
  <last_update_submitted_qc>February 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Immune Therapy</keyword>
  <keyword>DermaVir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

